Literature DB >> 9811776

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques.

P Ten Haaft1, B Verstrepen, K Uberla, B Rosenwirth, J Heeney.   

Abstract

To determine if a specific pathogenic threshold of plasma viral RNA could be defined irrespective of virus strain, RNA levels in the plasma of more than 50 infected rhesus macaques (Macaca mulatta) were measured. Animals were inoculated intravenously with either simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) strains of known pathogenic potential (SIV8980, SIVsmm-3, SIVmac32H/J5, SIVmac32H/1XC, reverse transcriptase-SHIV, SHIV89.6p) or with attenuated strains (SHIVW6.1D, SHIVsf13, SHIVhan-2, SIVmacDeltanef, SHIVsf33). In animals inoculated with nonpathogenic strains, shortly after the primary peak of viremia viral RNA levels declined and remained below 10(4) RNA equivalents/ml of plasma between 6 and 12 weeks postinoculation. Animals infected with documented pathogenic strains maintained viral RNA levels higher than 10(5) RNA equivalents/ml of plasma. In animals infected with strains with low virulence, a decline in plasma RNA levels was observed, but with notable individual variation. Our results demonstrate that the disease-causing potential was predicted and determined by a threshold plasma virus load which remained greater than 10(5) RNA equivalents/ml of plasma 6 to 12 weeks after inoculation. A threshold virus load value which remained below 10(4) RNA equivalents/ml of plasma was indicative of a nonpathogenic course of infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811776      PMCID: PMC110614     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.

Authors:  C S Dunn; B Hurtrel; C Beyer; L Gloeckler; T N Ledger; C Moog; M P Kieny; M Mehtali; D Schmitt; J P Gut; A Kirn; A M Aubertin
Journal:  AIDS Res Hum Retroviruses       Date:  1997-07-20       Impact factor: 2.205

2.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

3.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

Review 5.  Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac).

Authors:  P A Luciw; K E Shaw; R E Unger; V Planelles; M W Stout; J E Lackner; E Pratt-Lowe; N J Leung; B Banapour; M L Marthas
Journal:  AIDS Res Hum Retroviruses       Date:  1992-03       Impact factor: 2.205

6.  Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta.

Authors:  W M Bogers; R Dubbes; P ten Haaft; H Niphuis; C Cheng-Mayer; C Stahl-Hennig; G Hunsmann; T Kuwata; M Hayami; S Jones; S Ranjbar; N Almond; J Stott; B Rosenwirth; J L Heeney
Journal:  Virology       Date:  1997-09-15       Impact factor: 3.616

7.  A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.

Authors:  P Mooij; M van der Kolk; W M Bogers; P J ten Haaft; P Van Der Meide; N Almond; J Stott; M Deschamps; D Labbe; P Momin; G Voss; P Von Hoegen; C Bruck; J L Heeney
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

8.  Molecular cloning and characterization of a German HIV-1 isolate.

Authors:  U Sauermann; J Schneider; J Mous; U Brunckhorst; I Schedel; K D Jentsch; G Hunsmann
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

9.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120.

Authors:  C Cheng-Mayer; T Shioda; J A Levy
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14.

Authors:  S Dewhurst; J E Embretson; D C Anderson; J I Mullins; P N Fultz
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

View more
  51 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.

Authors:  R K S Ahmed; B Makitalo; K Karlen; C Nilsson; G Biberfeld; R Thorstensson
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

5.  International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.

Authors:  Claire Ham; Priya Srinivasan; Rigmor Thorstensson; Ernst Verschoor; Zahra Fagrouche; Leonardo Sernicola; Artur Ramos; Fausto Titti; Neil Almond; Neil Berry
Journal:  J Clin Microbiol       Date:  2010-04-28       Impact factor: 5.948

6.  The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies.

Authors:  F Li; C Leroux; J K Craigo; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load.

Authors:  Andrew R Wargo; Alison M Kell; Robert J Scott; Gary H Thorgaard; Gael Kurath
Journal:  Virus Res       Date:  2012-01-30       Impact factor: 3.303

8.  Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques.

Authors:  Edward T Mee; Neil Berry; Claire Ham; Ulrike Sauermann; Maria T Maggiorella; Frédéric Martinon; Ernst J Verschoor; Jonathan L Heeney; Roger Le Grand; Fausto Titti; Neil Almond; Nicola J Rose
Journal:  Immunogenetics       Date:  2009-04-01       Impact factor: 2.846

9.  High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx.

Authors:  Richard Onanga; Christopher Kornfeld; Ivona Pandrea; Jerome Estaquier; Sandrine Souquière; Pierre Rouquet; Virginie Poaty Mavoungou; Olivier Bourry; Souleymane M'Boup; Françoise Barré-Sinoussi; François Simon; Cristian Apetrei; Pierre Roques; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.